Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors

23 Apr 2019

Abstract excerpt

BACKGROUND: Epigenetic abnormalities are manifold in all solid tumors and include changes in chromatin configuration and DNA methylation. The authors designed a phase 1 study to evaluate the oral DNA methyltransferase inhibitor CC-486 combined with the histone deacetylase inhibitor romidepsin in advanced solid tumors with dose expansion to further evaluate pharmacodynamics and possible clinical benefit of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31012962
DOI: 10.1002/cncr.32138

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumorsPMID 31012962Read ↗

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenograftsSemantic proximity Read ↗

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsSemantic proximity Read ↗

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.Semantic proximity Read ↗

DNA Methylation–Targeted DrugsSemantic proximity Read ↗

Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

Histone Deacetylase Inhibitors: Emerging Mechanisms of ResistanceSemantic proximity Read ↗

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.Semantic proximity Read ↗

DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical applicationSemantic proximity Read ↗

5-Aza-4′-thio-2′-deoxycytidine, a New Orally Bioavailable Nontoxic “Best-in-Class”: DNA Methyltransferase 1–Depleting Agent in Clinical DevelopmentSemantic proximity Read ↗

Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinicSemantic proximity Read ↗

Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer StudySemantic proximity Read ↗

Designing Effective Protein Lysine and Arginine Methyltransferase Inhibitors for Chemotherapeutic TargetingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.